Jim Simons Corbus Pharmaceuticals Holdings, Inc. Transaction History

Renaissance Technologies LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.11 - $5.46 $75,661 - $3.76 Million	-687,831 Reduced 87.01%	102,700 $11,000
Q3 2022 Nov 14, 2022	SELL	$0.17 - $5.31 $142,175 - $4.44 Million	-836,329 Reduced 51.41%	790,531 $130,000
Q2 2022 Aug 12, 2022	BUY	$0.21 - $0.53 $98,630 - $248,924	469,669 Added 40.59%	1,626,860 $410,000
Q1 2022 May 13, 2022	BUY	$0.32 - $0.67 $291,677 - $610,698	911,491 Added 370.98%	1,157,191 $615,000
Q4 2021 Feb 11, 2022	BUY	$0.6 - $1.11 $147,420 - $272,727	245,700 New	245,700 $151,000
Q1 2021 May 13, 2021	SELL	$1.27 - $3.42 $1.22 Million - $3.29 Million	-962,100 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$0.94 - $1.89 $23,466 - $47,181	24,964 Added 2.66%	962,100 $1.2 Million
Q3 2020 Nov 13, 2020	BUY	$1.5 - $9.38 $1.12 Million - $6.99 Million	745,536 Added 389.11%	937,136 $1.69 Million
Q2 2020 Aug 13, 2020	BUY	$4.79 - $8.39 $917,764 - $1.61 Million	191,600 New	191,600 $1.61 Million

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $1.22B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.